
Route 92 Medical: Pioneering neuro-interventional technology for stroke treatment since 2015.
r92m.comCrawled Oct 14, 2026
Route 92 Medical presents an approach to refining access.
The page provides the latest news about Route 92 Medical.
Route 92 Medical seeks qualified people to join its team.
Route 92 Medical is a privately held medical technology company based in San Mateo, California, with a team of medical leaders.
Visit the Route 92 Medical page for investors.
Use the form on this page to contact Route 92 Medical.
The official website for Route 92 Medical.
Route 92 Medical, Inc. conducts business in the United States and other countries, including the European Union, and states that it is committed to protecting individuals’ privacy.
ROUTE 92 STANDARD TERMS AND CONDITIONS These Route 92 Standard Terms and Conditions (“Standard Terms”) govern the purchase of Route 92 Medical products (“Products”) by Customer from Route 92 Medical (“Route 92”). APM 0160-05.B
Route 92 Medical secures a $100 million corporate debt facility to bolster its financial stability. The funding supports ongoing product innovation and accelerates commercial expansion efforts. The company aims to leverage the capital for sustained growth in its medical technology offerings.
Oct 2026Yahoo FinanceNews article
Route 92 Medical receives U.S. FDA clearance for its **FreeClimb® 46 catheter with Tenzing® 4**, expanding its neurovascular catheter portfolio. The new device targets treatments in **smaller and more distal anatomies**, addressing unmet clinical needs in neurovascular interventions. The clearance strengthens the company’s position in advanced medical catheter solutions.
Sep 2026Route 92 MedicalNews article
Route 92 Medical secures $50 million in growth financing to accelerate commercial expansion. Sectoral Asset Management joins as a new investor in the round, supporting the company’s scaling efforts.
Apr 2026Route 92 MedicalNews article
Route 92 Medical has enrolled the first patient in the **SUMMIT RISE** clinical study. The trial will assess the company’s neurovascular intervention devices, targeting up to 500 participants to evaluate performance and safety.
Mar 2026Route 92 MedicalNews article